Sarah Moon

Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial

Robert H. Jones, Angela Casbard, Margherita Carucci et al. · The Lancet Oncology · 2020 · 227 citations · Full text

Medicine, Oncology, Pharmacology +17

Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial

Sacha J. Howell, Angela Casbard, Margherita Carucci et al. · The Lancet Oncology · 2022 · 143 citations · Full text

Medicine, Oncology, Pharmacology +17

Ingesting a pre-workout supplement containing caffeine, B-vitamins, amino acids, creatine, and beta-alanine before exercise delays fatigue while improving reaction time and muscular endurance

Brandon D. Spradley, Kristy R Crowley, Chih-Yin Tai et al. · Nutrition & Metabolism · 2012 · 85 citations · Full text

Education, Kinesiology, Physiology +17

Capivasertib (AZD5363) plus fulvestrant versus placebo plus fulvestrant after relapse or progression on an aromatase inhibitor in metastatic ER-positive breast cancer (FAKTION): A randomized, double-blind, placebo-controlled, phase II trial.

Robert H. Jones, Margherita Carucci, Angela Casbard et al. · Journal of Clinical Oncology · 2019 · 38 citations

Medicine, Oncology, Pharmacology +16

Fulvestrant plus capivasertib versus fulvestrant plus placebo after relapse or progression on an aromatase inhibitor in metastatic, estrogen receptor–positive breast cancer (FAKTION): Overall survival and updated progression-free survival data with enhanced biomarker analysis.

Robert H. Jones, Angela Casbard, Margherita Carucci et al. · Journal of Clinical Oncology · 2022 · 11 citations

Medicine, Oncology, Pharmacology +17